OBJECTIVE: Data on the association of resistin levels with markers of insulin resistance are highly contrasting in humans and very few studies about its role in inflammation are available. This study investigates associations between serum resistin levels and markers of insulin resistance, inflammation (C-reactive protein (CRP)) and of oxidative stress (nytrotirosine (NT)). SUBJECTS: A randomly collected sample of 300 men from a population-based cohort was analysed, separated into two groups according to body mass index (BMI) and waist values. RESULTS: Correlations between resistin and BMI, waist, triglyceride, uric acid, fasting glucose, insulin and Homeostasis Model Assessment (HOMA) values were significant in subjects with normal BMI, but not in overweight/obese subjects. In a multiple regression model, after multiple adjustments and exclusion of diabetic patients, only fasting glucose remained significantly associated with resistin levels. Otherwise, resistin is associated to CRP levels in all individuals, after multiple adjustments and exclusion of diabetic patients (in normal BMI b ¼ 0.82; 95% CI 0.21, 1.42; in overweight/obese b ¼ 0.43; 95% CI 0.10, 0.76). In the same model, resistin values are negatively related to NT levels in normal weight individuals (b ¼ À1.61; 95% CI À 0.77-2.45). CONCLUSIONS: Serum resistin is weakly associated with metabolic abnormalities in subjects with normal BMI, while in overweight/obese patients this correlation is not significant, perhaps due to the higher fat content in these subjects. Serum resistin is directly correlated with CRP and inversely to NT. An intriguing hypothesis, which needs to be tested, is that resistin is secreted in response to a chronic low-grade inflammation, and has antioxidant properties.
Introduction
Resistin, a member of the newly discovered family of cysteine-rich secretory proteins, has been described as a product of the adipose tissue, participating in the pathogenesis of insulin resistance, adipogenesis and inflammation in mice. 1, 2 The striking differences in the genomic organization and in the cellular source of resistin between human and rodents, however, make the biological effects found in the mouse not readily transferable to the human situation. [3] [4] [5] The studies performed in humans gave highly contrasting results: about a half found a correlation between resistin and body mass index (BMI), hyperglycaemia and insulin resistance, while half did not. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, in contrast to animals, human resistin expression is higher in mononuclear blood cells and other nonadipocyte cells of adipose tissue than in adipocytes. 5, 6, 10, 11 Thus, absolute serum resistin levels in obese or overweight patients might be increased, due to a higher content of fat and adipocytes, but correlations with BMI or with other metabolic parameters might not be linear (higher production of resistin in the stromovascular fraction of adipose tissue), explaining the discordant results of previous work. 5 Most previous studies were performed in small or highly selected cohorts; it has been suggested that selecting members at the extremes of insulin sensitivity might confer significant associations due to selection bias. 9 Furthermore, only few human studies (with contradictory results) about associations of resistin with inflammatory factors are available, 14, 18, [21] [22] [23] while a possible function of resistin in oxidative processes has been sporadically suggested. 24, 25 The aims of the present study were to evaluate the associations between serum resistin levels and a index of insulin resistance (Homeostasis Model Assessment (HOMA-IR)), a marker of inflammation (C-reactive protein (CRP)) and one of oxidative stress (nytrotirosine (NT)). A randomly collected sample of 300 men from a population-based cohort was studied; individuals with normal BMI and waist circumference were separately analysed from the remaining patients with overweight/obesity or with central obesity. The cross-sectional design of the study does not definitively establish causal relationships.
Patients and methods
The province of Asti (north-western Italy) consists of three Health districts, with similar population size, but different percentages of rural/urban areas. Out of 154 family physicians of the province (32.5, 35.7 and 31.8% from each district), six family physicians (two for each district), whose patients are representative of the three districts, accepted to join in the study. All their 45-64 y patients (1877 subjects, 33.7, 34.2 and 32.1% from each district) were identified and contacted, in order to perform a subsequent dietary intervention. The resident population of corresponding age, in the same area, shows the same percentage of: males, known diabetes, individuals for each 5-y class, and living in a rural area (data not shown).
A total of 1658 subjects (88.3%) agreed to be interviewed on personal habits, and to take part in a metabolic screening, giving written consent, whereas 219 refused. Mean age, level of education, percentage of males, known diabetes and subjects living in a rural area were almost overlapping in participating and missing patients. In all, 300 from this population-based cohort were randomly identified and submitted for measurement of resistin levels. Their clinical characteristics are similar to those of all the sample.
All procedures were in accordance with the Declaration of Helsinki.
In the morning, after an overnight fast, a venous blood sample was taken to measure fasting glucose, total and HDLcholesterol, uric acid, triglyceride, insulin, NT and resistin levels.
Weight and height were measured. Overweight and obese subjects were those with BMI, respectively, Z25 o30 kg/m 2 and Z30 kg/m 2 . Waist circumference was measured by a plastic tape measure at the level of the umbilicus; a value 4102 cm is considered abnormal for males, in line with the National Cholesterol Education Program (Adult Treatment Panel III) (NCEP-ATP III) criteria. 26 Systolic and diastolic blood pressures were measured twice with a standard mercury sphygmomanometer in a sitting position, after at least 10 min of rest. Values reported are the mean of the two determinations.
If the fasting serum glucose value was Z6.1 mmol/l, a second fasting glucose determination was then performed. Diabetes and impaired fasting glucose (IFG) were diagnosed according to published recommendations. 27 Insulin resistance was calculated from the HOMA-IR, according to published algorithm. 28 Data about alcohol intake, smoking habits, and exercise were collected for each subject. The level of physical activity during leisure was defined as light (inactive, o4 h/week physical activity) moderate (4 h/week) and heavy (44 h/ week, regular). 29 Serum glucose was measured by the glucose oxidase method (HITACHI 911 Analyser, Sentinel Ch., Milan, Italy), and serum insulin by immunoradiometric assay (Radim S.p.A., Pomezia, Italy; intra-assay variation coefficients (CV): 1.6-2.2%, interassay CV: 6.1-6.5%). Plasma triglycerides and HDL-cholesterol were measured by enzymatic colorimetric assay (HITACHI 911 Analyser, Sentinel Ch., Milan, Italy), the latter after precipitation of LDL and VLDL fractions using heparin-MnCl 2 solution and centrifugation at 41C.
Uric acid was evaluated with an enzymatic colorimetric method with uricase (HITACHI 911 Analyser, Sentinel Ch., Milan, Italy).
Serum CRP levels were determined by a high-sensitivity latex agglutination method on the HITACHI 911 Analyser (Sentinel Ch., Milan). The kit had a minimum detection of less than 0.05 mg/l and a measurable concentration range up to 160 mg/l. The intra-assay and interassay CVs were respectively 0.8-1.3 and 1.0-1.5%.
Plasma NT values were determined by an ELISA kit (HyCult Biotechnology b.v., sold in Italy by Pantec, Turin, Italy). The interassay precision was 774%; the intra-assay CV was 572%.
Serum resistin values were analysed by ELISA (BioVendor; Brno, Czech Republic); the intra-assay and interassay CVs were, respectively, 3.2-4.0 and 6.3-7.2%. All samples were run in blind.
Since the distribution of CRP, insulin, HOMA, triglyceride, NT and resistin values were highly skewed, their levels were log-transformed, in order to obtain a normal distribution. In all analyses the log-transformed values of these variables were used. For an easy interpretation, median (and s.e.) of not transformed values are reported.
Analysis of variance and the w 2 test were used to compare means for continuous variables or frequencies for discrete variables. Associations between resistin levels and other variables were evaluated by linear and multiple regression analyses, after adjustments for multiple confounders.
Results
We considered two groups: individuals with normal BMI (BMIo25 kg/m 2 ) and waist circumference (r102 cm), and the remaining subjects, overweight/obese or with central obesity. Their characteristics are described in Table 1 . The two groups are significantly different for all the metabolic parameters, as expected (Table 1) . Overweight patients show slightly higher levels of resistin, while NT values are not significantly different.
In all the cohort log-resistin is weakly associated with BMI, waist, diastolic blood pressure, triglyceride, uric acid, CRP and HOMA-IR values, and, inversely, associated with NT (Table 2 , left). The correlation coefficients between resistin and metabolic parameters according to BMI and waist group Resistin, insulin resistance and CRP S Bo et al are, surprisingly, higher in normal weight individuals (Table 2 , right). After excluding the three lean patients with diabetes mellitus, correlations with waist, fasting glucose, CRP, and NT levels (inverse) remain significant.
In a multiple regression model, after adjustment for age and BMI, and exclusion of the three cases of diabetes, logresistin is significantly associated with fasting glucose (b ¼ 8.18; 95% CI 0.75, 15.6, P ¼ 0.03), but not with waist circumference. However, after adjusting for CRP values, the association with fasting glucose is no longer significant.
In the same model, after adjustment for age, BMI and smoking, and exclusion of the diabetic patients, the associations between resistin and CRP levels are significant in normal weight and overweight individuals (respectively: normal BMI and waist n ¼ 93: b ¼ 0.82; 95% CI 0.21, 1.42, P ¼ 0.009; overweight/obese and/or central obesity n ¼ 176: b ¼ 0.43; 95% CI 0.10, 0.76, P ¼ 0.01).
Otherwise, resistin values are inversely associated to NT levels in normal weight individuals, in a multiple regression model, after adjustment for age, BMI and smoking (n ¼ 93: b ¼ À1.61; 95% CI À0.77-2.45, Po0.001). After adjusting for CRP data do not change.
In Figure 1 median resistin values for CRP tertile and NT tertile are reported. Resistin levels increase along with higher CRP values, but within each CRP tertile resistin values decrease by increasing NT tertile.
Discussion
Serum resistin levels are slightly higher in overweight/obese patients when compared to subjects with normal BMI and waist; however, surprisingly correlations between resistin values and metabolic variables are significant only in normal weight individuals (Table 2) . Furthermore, exclusion of the diabetic patients reduces greatly these associations. Serum Resistin, insulin resistance and CRP S Bo et al resistin, produced by the adipose tissue, might be present at higher circulating levels in subjects with higher fat content. However, the higher production of resistin by the nonfat fraction of adipose tissue. 5,6,10,11 might be a reason for the lack of associations found in our overweight/obese patients, in whom the adipocyte component of the adipose tissue might be greater with respect to the stromovascular fraction. This finding is in line with recent data showing a weak relationship between resistin and insulin sensitivity (evaluated by the insulin clamp technique) only in nonobese subjects. 19 Furthermore, it has already been hypothesized that the impact of resistin could be more important in a different biological setting, perhaps in the absence of severe obesity. 30 In subjects with normal waist circumference and BMI after excluding diabetic patients, only a weak association between serum resistin and fasting glycaemia could be detected. Thus, in diabetic patients, resistin could play a more important role, as described in literature. 14, 31 The modest reduction in glucose uptake with recombinant resistin, demonstrated in type 2 diabetic patients, might become relevant in poorly controlled patients, and contribute to the worsening of their metabolic condition. 14 In the cohort as a whole there is an independent association between serum resistin and CRP levels. Previous studies have suggested a relationship between this protein and inflammation.
14,18,21-23 High-sensitive CRP, a sensitive marker for systemic inflammation, predicts the occurrence of diabetes, the metabolic syndrome and atherosclerotic diseases and is highly associated to obesity and visceral fat. 32 One could hypothesize that the associations found between resistin levels and metabolic parameters are mediated, indeed, by the association of resistin with CRP levels, for which all studies are concordant in demonstrating a strong correlation with dysmetabolic alterations. 32 Accordingly, the association between fasting glucose and serum resistin levels is no longer significant, after introducing the CRP values in the multivariate analysis. Recently, more studies have supported the role of resistin as an inflammatory adipokine. 33, 34 Inflammatory endotoxin induced resistin in human macrophages involving the secretion of inflammatory cytokines, and in a human study, experimental endotoxemia induced a dramatic rise in circulating resistin levels, supporting inflammation as a hyper-resistinemic state. 34 According to this hypothesis there are studies about the reducing effects of thiazolidinedione (TZD) class of insulin sensitisers on resistin levels, 10, 14, 34 and the notion that these agents could decrease CRP values is reported. 35 Thus, the relationships between TZD and resistin might be modulated by the effect of the former on inflammation.
McTernan showed in a small cohort of type 2 diabetic patients and normoglycaemic controls a correlation only between serum resistin and CRP levels, but not with other metabolic parameters.
14 The same Author found also, as reported above, a reduced glucose uptake by recombinant resistin; it is however a modest effect, demonstrated in vitro. 14 Indeed, human resistin might preserve a weak intrinsic hyperglycaemic effect, as for the mouse resistin, from which, however, the human protein differs, seeming not well conserved in evolution. 4 Reactive nitrogen species are important mediators of inflammation; nitric oxide (NO) is an endothelium-related vasoactive substance that may be converted into potentnitrating oxidants. The reaction of NO with superoxide anion radicals (O 2 KÀ ) yields peroxynitrites (ONOOÀ), which can oxidise many bio-molecules. NT, generated from the oxidation of tyrosine, has been considered as a measure of ONOOÀ oxidative injury, and elevated plasma levels have been reported in diabetes, a condition associated with oxidative stress. [36] [37] [38] Resistin might act in response to inflammatory stimuli by an antioxidant mechanism; data suggesting participation of resistin in oxidative processes have been published. 24, 25 Smith 24 found a significant interaction among a single nucleotide polymorphism in the promoter of the human resistin gene and a marker of oxidative stress (NAD(P)H:quinone oxidoreductase I) and insulin resistance (HOMA-IR). Felipe 25 suggested that in mice retinoic acid, the acid form of vitamin A, inhibits the expression of resistin. In our cohort an inverse association between serum resistin and NT results from the multiple regression analysis, after adjusting for age, BMI, smoking and CRP levels. These relationships are evident within each tertile of CRP (Figure 1 ). Again, in overweight-obese patients, such relationships might not be linear and are confounded by their higher levels of resistin, proportional to the higher area of fat mass.
One is tempted to speculate that, in response to chronic low-grade inflammation, mononuclear blood cells would release this protein into the systemic circulation, where it acts by some antioxidant mechanisms.
The lack of a significant association between CRP and NT levels (data not shown) suggests that many interactions by multiple inflammatory or oxidative mediators are implicated.
It is necessary to note that the cross-sectional nature of these data does not definitively establish causal or temporal relationships, and should be considered hypothesis-generating only. We have studied only men in order to avoid any possible bias due to sex differences in serum resistin levels, which have been demonstrated to be higher in women. 12, 13, 17, 33 Nevertheless, the preliminary relationships suggested by these data seem worth of further investigations.
In conclusion, serum resistin is weakly associated to metabolic abnormalities in subjects with normal BMI and waist, while in overweight/obese patients this correlation is not significant, and, perhaps obscured by their higher fat content. The serum levels of resistin are directly correlated to CRP, a marker of chronic subclinical inflammation, highly associated to metabolic abnormalities, and inversely to NT, a product of free radical activity, suggesting that resistin could be secreted in response to chronic low-grade inflammation, and be involved in oxidative stress.
Resistin, insulin resistance and CRP S Bo et al
